SCHEMBL14745273

SCHEMBL14745273

COc1ccc(Cn2c3c(c(O)c(C(=O)O)c2=O)CCCc2c-3ccc3c2cc(C=O)n3C)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EDNRB P24530 8/20 0.43
EGLN1 Q9GZT9 3/20 0.36
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 1/20 0.35
FEN1 P39748 1/20 0.35
TSHR P16473 1/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
USP2 O75604 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14746295 0.89 EDNRB (0.44) EDNRBEGLN1ALDH1A1KDM4EFEN1
SCHEMBL14745934 0.87 EDNRB (0.38) EDNRBEGLN1ALDH1A1FEN1TSHR
SCHEMBL14746063 0.86 EDNRB (0.38) EDNRBEGLN1ALDH1A1FEN1TSHR
SCHEMBL14745808 0.84 EDNRB (0.39) EDNRBEGLN1ALDH1A1KDM4EFEN1
SCHEMBL14746001 0.82 EDNRB (0.39) EDNRBEGLN1ALDH1A1KDM4ETSHR
SCHEMBL14746216 0.81 EDNRB (0.40) EDNRBEGLN1ALDH1A1FEN1TSHR
SCHEMBL14745497 0.81 EDNRB (0.37) EDNRBEGLN1ALDH1A1KDM4EFEN1
SCHEMBL14746027 0.81 EDNRB (0.37) EDNRBEGLN1ALDH1A1KDM4EFEN1
SCHEMBL17498157 0.80 EDNRB (0.41) EDNRBEGLN1ALDH1A1TSHRMAPT
SCHEMBL14745842 0.79 P2RX3 (0.36) EDNRBEGLN1ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
WO-2016025933-A2 SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-02-18 WO disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP EDNRB 3885/4885EGLN1 712/4885ALDH1A1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.